Browsing: Volume 2 Issue 2 – February 2026

Longevity and Mortality Investor’s Editor’s Letter for the February 2026 issue.

One of the findings from the 2025 ELSA–Conning Life Settlement Investor Sentiment Study was that investors see life settlements sitting in their ‘resilience bucket,’ alongside private credit, infrastructure, and real assets.

There is plenty of investment work still to do even for those US plan sponsors that are in the last mile of their buy-out journey.

The latest data on excess mortality in England, published by the Office for Health Improvement and Disparities, shows that there were significantly fewer deaths among the older cohorts and the working-age population as well.

New policies that will fuel future trades in the life settlement market continue to be issued in healthy volumes, but in real terms, are slowly contracting.

Actuarial Guideline 55 is designed to provide regulators with more transparency into the asset adequacy of offshore asset-intensive life reinsurance structures.

The past 12 months have seen significant developments that are likely to shape mortality models among defined benefit pension scheme managers and sponsors alike, and possibly even have an impact on the pricing of de-risking deals.

The UK’s pension risk transfer market posted another strong year in 2025 both in terms of activity and aggregate premium transacted. Greg Winterton caught up with Alan Greenlees, Professional Trustee and Head of Risk Transfer at ZEDRA, to get his insights on a range of sub-topics within the space as 2026 begins in this month’s Q&A.

In today’s rapidly evolving insurance landscape, the arrival of AI in Life and Health underwriting and claims workflows is no longer a distant possibility – it’s already a reality.